ArticleJournal of the National Cancer Institute2026
Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThis population-based study aimed to quantify fracture risk after androgen receptor pathway inhibitors in advanced prostate cancer patients by preexisting health conditions.
methodsPatients were identified from the Surveillance, Epidemiology, and End Results-Medicare files who received abiraterone acetate with prednisone or enzalutamide between January 1, 2013, and December 31, 2020. Health and fracture history were based on claims 1 year before androgen receptor pathway inhibitor with follow-up through December 31, 2020. The main outcome of the study was the cumulative fracture risk after first date of androgen receptor pathway inhibitor. Fine and Gray subdistribution hazard model was used to obtain adjusted relative risks with confounding factors.
resultsThis study included 10 463 patients (6037 treated with abiraterone acetate with prednisone; 4426 treated with enzalutamide). The 3-year fracture risk after androgen receptor pathway inhibitor was high, exceeding 25% among those without a prior fracture. Among 1445 men with a fracture the year before androgen receptor pathway inhibitor, 3-year fracture risk exceeded 50% and remained high (above 44%) despite using bone health agents. A recent history of fracture was associated with a 2.84-fold fracture risk (adjusted hazard ratio [HR] = 2.84, 95% confidence interval [CI] = 2.58 to 3.12). Preexisting osteoporosis and a comorbidity score of 2 or higher were associated with 15% (adjusted HR = 1.15, 95% CI = 1.03 to 1.29) and 11% (adjusted HR = 1.11, 95% CI = 1.00 to 1.24) higher fracture risks. Bone health agent use was associated with a 23% lower fracture risk (adjusted HR = 0.77, 95% CI = 0.70 to 0.83).
conclusionsFracture risk after androgen receptor pathway inhibitor was high, exceeding 44% within 3 years in those with prior fractures despite bone health agents, suggesting limited benefit in patients with poor bone quality. Early identification and intervention for patients at high risk of fractures are critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.